$18.09
0.593.37%
Last update: Nov 13, 9:30 AM
Cue Biopharma Inc
CUENASDAQ
Cue Biopharma rose 0.4% from $18.59 to $18.66, behind the S&P 500's +12.7%. Its worst day was Apr 28 (−30.5%), and its low came Apr 6 at $5.31.
Nov 13, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Cue Biopharma shares rose 34.8%, while the S&P 500 fell 0.0%.
+34.8% · S&P 500 0.0%
EPS of $0.30 beat the $-2.70 estimate on $21.9M revenue (est. $1.0M).
−12.8% · S&P 500 +0.3%
Story events cover the past 12 months · Times ET
Cue Biopharma closed at its lowest level of the year, 71.4% below where the year started.
−1.6% · S&P 500 +0.5%
Cue Biopharma shares rose 65.4%, while the S&P 500 rose 0.8%.
+65.4% · S&P 500 +0.8%
Cue Biopharma shares rose 106.4%, while the S&P 500 rose 0.3%.
+106.4%, the year's best day, on 19M shares, the year's heaviest volume · S&P 500 +0.3%
EPS of $-1.08 missed the $-0.11 estimate on $5.7M revenue (est. $1.0M).
−9.2% · S&P 500 −1.2%
EPS of $-24.14 missed the $-1.38 estimate on $7.9M revenue (est. $3.0M).
−19.2% · S&P 500 −0.5%
Cue Biopharma closed at its highest level of the year, 103.6% above where the year started.
+10.7% · S&P 500 +0.9%
Where it ended: a close of $18.66 on Nov 11, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-2.60, revenue est. $1.0M).
Nothing in the past 12 months.
All CUE dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CUE and SPY from Benzinga historical bars. Not investment advice.
